ASCA101 IND approval for Phase 1

Metafines Corp., a specialized company to develop metabolic anti-cancer drug, announced that it received the phase1 IND approval with its low toxicity metabolic anti-cancer drug ‘ASCA101’ from Ministry of Food and Drug Safety(MFDS) as of June 9, 2021. Based on this, Metafines Corp. will launch Phase 1 for ASCA101 from September 2021.

Phase 1 for ASCA101, which was approved for clinical protocol this time, will be conducted with 30 patients of advanced solid cancer. In this clinical study, focusing on factors that include acceptability, safety, pharmacokinetics & pharmacodynamics and anti-cancer activity will be assessed.

3 institutions (Seoul National Univ. Bundang Hospital, Seoul ST.MARY’S Hospital, CHA Univ. Bundang Medical Center) will conduct the clinical trial. 

"from the approval of ASCA101 phase1 IND this time, clinical phase 1 for ASCA101 will be conducted rapidly”

the person concerned said “We will do our best to help Metafines enter the global market as soon as possible through rapid clinical progress.”

*Related Article